Indication
Transitional cell carcinoma of the urinary tract
Transitional cell carcinoma of the urinary tract, also referred to as urothelial carcinoma, is a malignancy arising from the specialized transitional epithelial lining of the urinary system. Read more about Transitional cell carcinoma of the urinary tract
7 drugs 5 manufacturers
Drugs that treat it
Common Transitional cell carcinoma of the urinary tract therapies.
OPDIVO (nivolumab)
KEYTRUDA (pembrolizumab)
BAVENCIO (avelumab)
PADCEV (enfortumab vedotin-ejfv)
PADCEV (enfortumab vedotin-ejfv)
KEYTRUDA QLEX (pembrolizumab-berahyaluronidase alfa-pmph)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonTransitional cell carcinoma of the urinary tract, also referred to as urothelial carcinoma, is a malignancy arising from the specialized transitional epithelial lining of the urinary system.
It most commonly develops in the urinary bladder, but can originate anywhere along the urinary tract, including the renal pelvis, ureters, and urethra, predominantly affecting older adults.
Pathophysiologically, the tumor often exhibits a field cancerization effect characterized by multifocality and a high tendency for recurrence throughout the urothelium.
Clinically, it typically presents with painless gross or microscopic hematuria, dysuria, or urinary frequency, and lesions can range from noninvasive, low-grade papillary neoplasms to high-grade, muscle-invasive carcinomas prone to systemic metastasis.
- nih.gov
Transitional cell carcinoma of the urinary tract, also referred to as urothelial carcinoma, is a malignancy arising from the specialized transitional epithelial lining of the urinary system
- cancer.gov
Transitional cell carcinoma of the urinary tract, also referred to as urothelial carcinoma, is a malignancy arising from the specialized transitional epithelial lining of the urinary system It most commonly develops in the urinary bladder, but can originate anywhere along the urinary tract, including the renal pelvis, ureters, and urethra, predominantly affecting older adults
- nih.gov
It most commonly develops in the urinary bladder, but can originate anywhere along the urinary tract, including the renal pelvis, ureters, and urethra, predominantly affecting older adults Pathophysiologically, the tumor often exhibits a field cancerization effect characterized by multifocality and a high tendency for recurrence throughout the urothelium
- nih.gov
Pathophysiologically, the tumor often exhibits a field cancerization effect characterized by multifocality and a high tendency for recurrence throughout the urothelium
- nih.gov
Clinically, it typically presents with painless gross or microscopic hematuria, dysuria, or urinary frequency, and lesions can range from noninvasive, low-grade papillary neoplasms to high-grade, muscle-invasive carcinomas prone to systemic metastasis
- nih.gov
Clinically, it typically presents with painless gross or microscopic hematuria, dysuria, or urinary frequency, and lesions can range from noninvasive, low-grade papillary neoplasms to high-grade, muscle-invasive carcinomas prone to systemic metastasis
- moffitt.org
Clinically, it typically presents with painless gross or microscopic hematuria, dysuria, or urinary frequency, and lesions can range from noninvasive, low-grade papillary neoplasms to high-grade, muscle-invasive carcinomas prone to systemic metastasis
Personalize your experience
Follow Transitional cell carcinoma of the urinary tract and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.